Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?

BACKGROUND: The time interval between palliative thoracic radiotherapy and bevacizumab treatment strongly influences the frequency of adverse events (AEs) when both are concurrently applied to patients with advanced lung cancer. Herein, we aimed to elucidate the optimal time interval between the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiu, Weigang, Guo, Xiaotong, Yu, Min, Li, Yanying, Xu, Yong, Zhu, Jiang, Luo, Jingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234832/
https://www.ncbi.nlm.nih.gov/pubmed/35770233
http://dx.doi.org/10.1177/11795549221106462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234832/
https://www.ncbi.nlm.nih.gov/pubmed/35770233
http://dx.doi.org/10.1177/11795549221106462

Ejemplares similares